BI-1387446
- Generic Name
- BI-1387446
A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 39
- Registration Number
- NCT04147234
- Locations
- 🇪🇸
Hospital Vall d'Hebron-Barcelona-47683, Barcelona, Spain
🇺🇸Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇪🇸CIO Clara Campal, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath